The National Service Framework for Older People

In 1997, the new Labour Government in the UK embarked on an ambitious programme of reform. One of the key changes has been the publication of a series of National Service Frameworks. The National Service Framework for Older People (NSFOP) sets out a 10-year programme that has as its principal standard rooting out age discrimination. Together with its companion documents, a series of robust milestones and standards are set out that have to be met. Although generally welcomed by the profession, the NSFOP has been criticised by some because it mandates the initiation of new ‘intermediate care’ services that may be seen as denying older people the opportunity for admission to mainstream hospital care. Monitoring tools covering both procedures and prescribing have been developed. The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.In tackling age discrimination, both direct and indirect barriers to effective prescribing need to be considered. The evidence base on the effectiveness of medication in older people is more limited due to the previous systematic exclusion of older people from clinical trials. The consequent lack of evidence of efficacy, coupled with perhaps a natural reluctance to prescribe potentially toxic medication, may lead to underprescribing. Other indirect causes of age discrimination may include difficulties for older people attending hospitals for drug monitoring, and the difficulties of translating the results of trials into meaningful endpoints that older patients can understand and thus make valid decisions about whether they wish to take the particular drug or not. At the same time as the NSFOP argues against age discrimination, other government policies may operate in a contradictory manner. Examples include the trend to make drugs available over the counter in pharmacies and for which the patient has to pay rather than receive them free, the restriction of some prescription-only drugs from the health service, and the need for referral to specialist services for some drugs, e.g. sildefanil, which older people may be reluctant to access. Successfully combating age discrimination is likely to require a regulatory framework, continued monitoring, tackling indirect forms of discrimination, as well as embedding antidiscrimination policies in all facets of health education.

[1]  Robert Baldwin National Service Framework for Older People , 2003 .

[2]  H. Kohli Scottish Medicines Consortium. , 2005, The National medical journal of India.

[3]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[4]  R. Kronmal,et al.  Lessons from the Stroke Prevention in Atrial Fibrillation Trials , 2003, Annals of Internal Medicine.

[5]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[6]  E. Krueger,et al.  Subarachnoid Hemorrhage from an Aneurysm in a Patient with Thrombocytopenic Purpura , 1957, Neurology.

[7]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[8]  Paul McCafferty,et al.  Living independently: A study of the housing needs of elderly and disabled people , 1994 .

[9]  A. Dart,et al.  Age and the treatment gap in the use of statins , 2003, The Lancet.

[10]  N. Dudley,et al.  The influence of age on policies for admission and thrombolysis in coronary care units in the United Kingdom. , 1992, Age and ageing.

[11]  J. Neilson Assessment of fetal nuchal translucency test for Down's syndrome , 1997, The Lancet.

[12]  K. Shulman,et al.  Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence , 2003, BMJ : British Medical Journal.

[13]  N. Powe,et al.  Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. , 2000, Circulation.

[14]  C. Warwick The new NHS: modern dependable , 1998 .

[15]  R. Tallis,et al.  A new beginning for care for elderly people? , 2001, BMJ : British Medical Journal.

[16]  C. Bulpitt,et al.  The MRC trial of assessment and management of older people in the community: objectives, design and interventions [ISRCTN23494848] , 2002, BMC health services research.

[17]  Shaw Ab Ensuring Equity and Quality of Care for Elderly People , 1995, Journal of the Royal College of Physicians of London.

[18]  J A Paris,et al.  Royal College of Physicians of London , 1848, Provincial medical & surgical journal.

[19]  M. Mckee,et al.  Rationing treatment on the NHS--still a political issue. , 2003, Journal of the Royal Society of Medicine.

[20]  Thompson G. Robinson,et al.  National Clinical Guidelines for Stroke. , 2001 .

[21]  A. Bowling,et al.  Age- and sex-related bias in the management of heart disease in a district general hospital. , 2002, Age and ageing.

[22]  C. Bulpitt,et al.  Hypertension in the Very Elderly Trial (HYVET) , 2001, Drugs & aging.

[23]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[24]  C. Bulpitt,et al.  Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub-group analysis on entry stratification. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[25]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[26]  Adelina Comas-Herrera,et al.  Relying on informal care in the new century? Informal care for elderly people in England to 2031 , 2000, Ageing and Society.

[27]  Bruno Vellas,et al.  Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden , 2003, Journal of the American Geriatrics Society.

[28]  B. O. Williams,et al.  Clinical Trials in the Elderly , 1996 .

[29]  P. Crome,et al.  Appropriate prescribing in older people , 2002 .

[30]  Alan Williams,et al.  The rationing debate: Rationing health care by age: The case for , 1997 .

[31]  Laing and Buisson,et al.  Care of elderly people : market survey 2001 , 2001 .

[32]  T. Strasser,et al.  MORTALITY AND MORBIDITY RESULTS FROM THE EUROPEAN WORKING PARTY ON HIGH BLOOD PRESSURE IN THE ELDERLY TRIAL , 1985, The Lancet.

[33]  J. Rawles,et al.  Women and myocardial infarction: agism rather than sexism? , 1995, British heart journal.

[34]  D. Greenblatt,et al.  Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. 1978. , 1978, British journal of clinical pharmacology.

[35]  Jingwu Z. Zhang,et al.  A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. , 2002, Clinical therapeutics.

[36]  P. Crome What's different about older people. , 2003, Toxicology.

[37]  Mary T. Roth,et al.  Secondary Prevention of Coronary Heart Disease in the Elderly , 2003, The Annals of pharmacotherapy.

[38]  J. Castillo,et al.  Public Perception of Stroke in Spain , 2003, Cerebrovascular Diseases.

[39]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[40]  I. Starkey,et al.  Elderly and younger patients selected to undergo coronary angiography. , 1991, BMJ.